Applied Therapeutics, Inc. (NASDAQ:APLT) CFO Charles Silberstein Sells 5,047 Shares

Applied Therapeutics, Inc. (NASDAQ:APLT) CFO Charles Silberstein sold 5,047 shares of the firm’s stock in a transaction dated Tuesday, June 8th. The shares were sold at an average price of $21.42, for a total value of $108,106.74. Following the sale, the chief financial officer now directly owns 87,803 shares in the company, valued at $1,880,740.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ:APLT opened at $22.67 on Friday. The stock has a market capitalization of $591.26 million, a P/E ratio of -4.86 and a beta of 1.16. Applied Therapeutics, Inc. has a 12 month low of $13.58 and a 12 month high of $49.88. The stock has a 50-day moving average price of $17.73.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings data on Monday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.01. As a group, research analysts anticipate that Applied Therapeutics, Inc. will post -4.41 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in Applied Therapeutics by 403.2% during the first quarter. Royal Bank of Canada now owns 1,706 shares of the company’s stock valued at $32,000 after purchasing an additional 1,367 shares during the last quarter. Ancora Advisors LLC bought a new position in shares of Applied Therapeutics in the 4th quarter valued at about $55,000. Citigroup Inc. grew its position in Applied Therapeutics by 114.4% in the fourth quarter. Citigroup Inc. now owns 3,836 shares of the company’s stock worth $85,000 after acquiring an additional 2,047 shares in the last quarter. JPMorgan Chase & Co. grew its position in Applied Therapeutics by 20.8% in the fourth quarter. JPMorgan Chase & Co. now owns 6,143 shares of the company’s stock worth $135,000 after acquiring an additional 1,056 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in Applied Therapeutics during the fourth quarter worth approximately $151,000. Institutional investors own 55.73% of the company’s stock.

Several research firms recently issued reports on APLT. Zacks Investment Research cut Applied Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 24th. Robert W. Baird reaffirmed a “buy” rating and set a $35.00 price objective on shares of Applied Therapeutics in a report on Sunday, March 21st.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

Further Reading: Options Trading

Insider Buying and Selling by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.